金吾财讯 | 绿叶制药(02186)公布，集团的创新药赞必佳（注射用芦比替定）作为被纳入优先审评审批程序的品种，已获得中国国家药品监督管理局的上市批准，适用于治疗含铂化疗中或化疗后疾病进展的转移性小细胞肺癌(SCLC)成人患者。公司称，赞必佳是一种选择性的致癌基因转录抑制剂，在抑制肿瘤基因转录、导致肿瘤细胞雕亡的同时，可调节肿瘤微环境，进一步发挥抗肿瘤作用。该产品于2020年获得美国食品药品监督管理局(FDA)的附条件批准。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.